title: Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
abstract: Lovastatin, a specific inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, HMG-CoA reductase, has been shown to be highly effective in lowering serum cholesterol in animals and humans and thus represents a promising approach to the treatment and prevention of cardiovascular disease. During the preclinical safety assessment of lovastatin, oral doses that were tolerated by dogs, rats and mice were found to be lethal to rabbits in subacute studies. Postmortem findings in rabbits consisted of centrilobular hepatic necrosis, frequently accompanied by renal tubular necrosis and occasionally gallbladder necrosis. The liver lesions were associated with up to 300-fold elevations in serum aspartate and alanine aminotransferase activities, whereas the kidney lesions resulted in accumulations of serum urea nitrogen and creatinine. The organ damage was preceded by a progressive decline in food consumption and loss of body weight. All histopathological and serum biochemical changes induced by lovastatin were completely prevented by coadministration of mevalonate, the product of the inhibited HMG-CoA reductase enzyme. In addition, administration of mevalonate after the onset of lovastatin-induced hepatotoxicity effectively reversed the toxicity despite continued drug treatment. These findings indicated that the toxicity of high doses of lovastatin to rabbits is a consequence of a highly exaggerated pharmacologic action in blocking mevalonate synthesis. However, supplementation of lovastatin-treated rabbits with oral doses of the major product of mevalonate metabolism, cholesterol, paradoxically enhanced the liver and kidney damage, which suggested that the toxicity of lovastatin stemmed from depletion of a nonsterol metabolite(s) of mevalonate critical for cell viability.
authors.affiliation: Department of Safety Assessment, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania.
authors.forename: D J
authors.initials: DJ
authors.lastname: Kornbrust
authors.forename: J S
authors.initials: JS
authors.lastname: MacDonald
authors.forename: C P
authors.initials: CP
authors.lastname: Peter
authors.forename: D M
authors.initials: DM
authors.lastname: Duchai
authors.forename: R J
authors.initials: RJ
authors.lastname: Stubbs
authors.forename: J I
authors.initials: JI
authors.lastname: Germershausen
authors.forename: A W
authors.initials: AW
authors.lastname: Alberts
mesh_terms: D000818:Animals; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D004435:Eating / Q000187:drug effects; D005260:Female; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008148:Lovastatin / Q000633:toxicity*; D008798:Mevalonic Acid / Q000494:pharmacology; D011817:Rabbits; D013045:Species Specificity
chemical_list: D002791:Cholesterol, Dietary; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin; D008798:Mevalonic Acid